RMRobert L. Medcalf

Robert L. Medcalf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert L. Medcalf has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The plasminogen activator inhibitor 2 transcript is destabilized via a multi‐component 3′ UTR localized adenylate and uridylate‐rich instability element in an analogous manner to cytokines and oncogenes

    by Stan Stasinopoulos, Mythily Mariasegaram, Chris Gafforini, Yoshikuni Nagamine, Robert L. Medcalf

    Plasminogen activator inhibitor type 2 (PAI‐2; SERPINB2) is a highly‐regulated gene that is subject to both transcriptional and post‐transcriptional control. For the latter case, inherent PAI‐2 mRNA instability was previously shown to require a nonameric adenylate‐uridylate element in the 3′ UTR. However, mutation of this site was only partially effective at restoring complete mRNA stabilization. In the present study, we have identified additional regulatory motifs within the 3′ UTR that cooperate with the nonameric adenylate‐uridylate element to promote mRNA destabilization. These elements are located within a 74 nucleotide U‐rich stretch (58%) of the 3′ UTR that flanks the nonameric motif; deletion or substitution of this entire region results in complete mRNA stabilization. These new elements are conserved between species and optimize the destabilizing capacity with the nonameric element to ensure complete mRNA instability in a manner analogous to some class I and II adenylate‐uridylate elements present in transcripts encoding oncogenes and cytokines. Hence, post‐transcriptional regulation of the PAI‐2 mRNA transcript involves an interaction between closely spaced adenylate‐uridylate elements in a manner analogous to the post‐transcriptional regulation of oncogenes and cytokines.


  • Open Access

    A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury

    by Andre L. Samson, Rachael J. Borg, Be'Eri Niego, Connie H. Y. Wong, Peter J. Crack, Tang Yongqing, Robert L. Medcalf

    Tissue-type plasminogen activator (tPA) is an extracellular protease that converts plasminogen into plasmin. For tPA to generate plasmin under biologic conditions, a cofactor must first bring tPA and plasminogen into physical proximity. Fibrin provides this cofactor for tPA-mediated plasmin generation in blood. Despite being naturally devoid of fibrin(ogen), tPA-mediated plasmin formation also occurs in the brain. The fibrin-like cofactor(s) that facilitates plasmin formation in the injured brain has remained unknown. Here we show that protein aggregates formed during neuronal injury provide a macromolecular, nonfibrin cofactor that promotes tPA-mediated plasmin formation and subsequent cell breakdown. The binding of plasminogen and tPA to these protein aggregates occurs via distinct mechanisms. Importantly, nonneuronal cell types also exhibit this cofactor effect upon injury, indicating a general phenomenon. This novel cofactor identified in nonviable cells has ramifications for ischemic stroke where tPA is used clinically and where plasmin activity within the injured brain is unwanted. A means of selectively inhibiting the binding of tPA to nonviable cells while preserving its association with fibrin may be of benefit for the treatment of ischemic stroke.


  • Open Access

    Tissue‐type plasminogen activator requires a co‐receptor to enhance NMDA receptor function

    by Andre L. Samson, Simon T. Nevin, David Croucher, Be’eri Niego, Philip B. Daniel, Thomas W. Weiss, Eliza Moreno, Denis Monard, Daniel A. Lawrence, Robert L. Medcalf

    Glutamate is the main excitatory neurotransmitter of the CNS. Tissue‐type plasminogen activator (tPA) is recognized as a modulator of glutamatergic neurotransmission. This attribute is exemplified by its ability to potentiate calcium signaling following activation of the glutamate‐binding NMDA receptor (NMDAR). It has been hypothesized that tPA can directly cleave the NR1 subunit of the NMDAR and thereby potentiate NMDA‐induced calcium influx. In contrast, here we show that this increase in NMDAR signaling requires tPA to be proteolytically active, but does not involve cleavage of the NR1 subunit or plasminogen. Rather, we demonstrate that enhancement of NMDAR function by tPA is mediated by a member of the low‐density lipoprotein receptor (LDLR) family. Hence, this study proposes a novel functional relationship between tPA, the NMDAR, a LDLR and an unknown substrate which we suspect to be a serpin. Interestingly, whilst tPA alone failed to cleave NR1, cell‐surface NMDARs did serve as an efficient and discrete proteolytic target for plasmin. Hence, plasmin and tPA can affect the NMDAR via distinct avenues. Altogether, we find that plasmin directly proteolyses the NMDAR whilst tPA functions as an indirect modulator of NMDA‐induced events via LDLR engagement.


  • Two conserved regions within the tissue-type plasminogen activator gene promoter mediate regulation by brain-derived neurotrophic factor

    by Philip B. Daniel, Wolfram Lux, Andre L. Samson, Wolf-Dieter Schleuning, Be'Eri Niego, Thomas W. Weiss, Anna Tjärnlund-Wolf, Robert L. Medcalf

    Tissue‐type plasminogen activator (t‐PA) has recently been identified as a modulator of neuronal plasticity and can initiate conversion of the pro‐form of brain‐derived neurotrophic factor (BDNF) into its mature form. BDNF also increases t‐PA gene expression implicating t‐PA as a downstream effector of BDNF function. Here we demonstrate that BDNF‐mediated induction of t‐PA mRNA requires an increase in t‐PA gene transcription. Reporter constructs harboring 9.5 kb of the human t‐PA promoter conferred BDNF‐responsiveness in transfected mouse primary cortical neurons. This regulation was recapitulated in HEK 293 cells coexpressing the TrkB neurotrophin receptor. t‐PA promoter‐deletion analysis revealed the presence of two BDNF‐responsive domains, one located between −3.07 and −2.5 kb and the other within the proximal promoter. The upstream region was shown to confer BDNF responsiveness in a TrkB‐dependent manner when attached to a heterologous promoter. We also identify homologous regions within the murine and bovine t‐PA gene promoters and demonstrate that the equivalent upstream murine sequence functions as a BDNF‐responsive enhancer when inserted 5′ of the human proximal t‐PA promoter. Hence, BDNF‐mediated induction of t‐PA transcription relies on conserved modular promoter elements including a novel upstream BDNF‐responsive domain and the proximal t‐PA gene promoter.


  • Open Access

    Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo

    by Thomas W. Weiss, Andre L. Samson, Be'ERi Niego, Philip B. Daniel, Robert L. Medcalf

    Oncostatin M (OsM) is a member of the interleukin (IL)‐6 family of cytokines and is well known for its role in inflammation, cell proliferation, and hematopoiesis. OsM, together with its glycoprotein 130 containing receptor complex, is expressed and regulated in most cells of the central nervous system (CNS), yet the function of OsM within this compartment is poorly understood. Here we have investigated the effect of OsM using in vitro and in vivo models of excitotoxic injury. Using primary cultures of mouse cortical neurons, OsM was shown to reduce N‐methyl‐D‐aspartate (NMDA) ‐induced neuronal death by 50% when added simultaneously with NMDA while pretreatment of neurons with OsM fully prevented NMDA toxicity indicating a profound protective effect of this cytokine. OsM was also shown to inhibit NMDA‐mediated increase in levels of free intracellular calcium and to selectively reduce neuronal expression of the NR2C subunit of the NMDA receptor. Finally, using an in vivo model of excitotoxic injury, OsM significantly reduced the NMDA‐induced lesion volume when coinjected with NMDA into the mouse striatum. Taken together, these results identify OsM as a powerful neuroprotective cytokine and provide a rational foundation to explore the therapeutic potential for OsM in diseases of the CNS.—Weiss, T. W., Samson, A. L., Niego, B., Daniel, P. B., Medcalf, R. L. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J. 20, E1636 –E1645 (2006)


  • The undecided serpin

    by Robert L. Medcalf, Stan J. Stasinopoulos

    Plasminogen activator inhibitor type‐2 (PAI‐2) is a nonconventional serine protease inhibitor (serpin) with unique and tantalizing properties that is generally considered to be an authentic and physiological inhibitor of urokinase. However, the fact that only a small percentage of PAI‐2 is secreted has been a long‐standing argument for alternative roles for this serpin. Indeed, PAI‐2 has been shown to have a number of intracellular roles: it can alter gene expression, influence the rate of cell proliferation and differentiation, and inhibit apoptosis in a manner independent of urokinase inhibition. Despite these recent advances in defining the intracellular function of PAI‐2, it still remains one of the most mysterious and enigmatic members of the serpin superfamily.